DEUTERATED FINGOLIMOD
    11.
    发明申请
    DEUTERATED FINGOLIMOD 审中-公开
    检测FINGOLIMOD

    公开(公告)号:US20120141513A1

    公开(公告)日:2012-06-07

    申请号:US13311171

    申请日:2011-12-05

    摘要: This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist, such as fingolimod.

    摘要翻译: 本发明涉及作为芬戈莫德的氘化衍生物及其药学上可接受的盐的新化合物。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所公开的化合物和组合物在治疗通过施用溶血磷脂edg1(S1P1)受体激动剂如芬戈莫德有益治疗的疾病和病症的方法中的用途 。

    Deuterium Modified Benzimidazoles
    12.
    发明申请
    Deuterium Modified Benzimidazoles 审中-公开
    氘改性苯并咪唑

    公开(公告)号:US20120058085A1

    公开(公告)日:2012-03-08

    申请号:US13320653

    申请日:2010-05-14

    摘要: This invention relates to derivatives of 1-(p-chlorobenzyl)-2-(1-pyrrolidinylmethyl)benzimidazole according to Formula I wherein at least one Y is deuterium described herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of hepatitis C virus (HCV) RNA replication.

    摘要翻译: 本发明涉及式(I)的1-(对氯苄基)-2-(1-吡咯烷基甲基)苯并咪唑的衍生物,其中至少一个Y是本文所述的氘和其药学上可接受的盐。 本发明还提供包含本发明化合物的组合物和这些组合物在治疗通过施用丙型肝炎病毒(HCV)RNA复制物的抑制剂有益治疗的疾病和病症的方法中的用途。

    FLUOROURACIL DERIVATIVES
    13.
    发明申请
    FLUOROURACIL DERIVATIVES 审中-公开
    氟尿嘧啶衍生物

    公开(公告)号:US20130109707A1

    公开(公告)日:2013-05-02

    申请号:US13581077

    申请日:2011-02-28

    IPC分类号: C07D239/553 A61K31/513

    摘要: This invention relates to novel fluorouracil derivatives of Formula I or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a thymidylate synthase inhibitor.

    摘要翻译: 本发明涉及式I的新型氟尿嘧啶衍生物或其药学上可接受的盐。 本发明还提供了包含本发明化合物和这种组合物在治疗通过施用胸苷酸合酶抑制剂有益治疗的疾病和病症的方法中的用途的组合物。

    Deuterated fingolimod
    14.
    发明申请
    Deuterated fingolimod 审中-公开
    笨拙的芬戈莫德

    公开(公告)号:US20090176744A1

    公开(公告)日:2009-07-09

    申请号:US12290645

    申请日:2008-10-31

    摘要: This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist, such as fingolimod.

    摘要翻译: 本发明涉及作为芬戈莫德的氘化衍生物及其药学上可接受的盐的新化合物。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所公开的化合物和组合物在治疗通过施用溶血磷脂edg1(S1P1)受体激动剂如芬戈莫德有益治疗的疾病和病症的方法中的用途 。

    Deuterated pyrazinoisoquinoline compounds
    15.
    发明授权
    Deuterated pyrazinoisoquinoline compounds 有权
    氘化吡嗪异喹啉化合物

    公开(公告)号:US08889687B2

    公开(公告)日:2014-11-18

    申请号:US13411198

    申请日:2012-03-02

    摘要: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.

    摘要翻译: 本发明在一个实施方案中涉及式Ia化合物; 其中指定(R)表示指定的碳具有(R)立体化学; 并且其中Z1是氢或氟; Z2是氢,氘或氟; Z3是氘; Z4是氟; m为0〜10的整数; n为0〜2的整数; 条件是:m + n的和不超过10; 并且当Z1和Z2均为氢时,m + n的和大于0,以及其药学上可接受的盐。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。

    Deuterated pyrazinoisoquinoline compounds
    16.
    发明授权
    Deuterated pyrazinoisoquinoline compounds 有权
    氘化吡嗪异喹啉化合物

    公开(公告)号:US08563554B2

    公开(公告)日:2013-10-22

    申请号:US13256787

    申请日:2010-03-16

    IPC分类号: A61K31/495

    摘要: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel, such as compounds of formula (I): or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.

    摘要翻译: 本发明涉及吡嗪并异喹啉衍生物的新化合物及其药学上可接受的盐。 更具体地,本发明涉及作为吡喹酮的衍生物的新的吡嗪并喹啉衍生物,例如式(I)的化合物或其药学上可接受的盐。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。

    Fluorinated diaryl urea derivatives
    17.
    发明授权
    Fluorinated diaryl urea derivatives 有权
    氟化二芳基脲衍生物

    公开(公告)号:US08410082B2

    公开(公告)日:2013-04-02

    申请号:US13320646

    申请日:2010-05-20

    CPC分类号: C07D213/81 C07B59/002

    摘要: This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases.

    摘要翻译: 本发明涉及新的二芳基脲化合物,其衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用多种激酶抑制剂有益治疗的疾病和病症的方法中的用途。

    PYRAZINOISOQUINOLINE COMPOUNDS
    19.
    发明申请
    PYRAZINOISOQUINOLINE COMPOUNDS 有权
    吡咯烷酮化合物

    公开(公告)号:US20120149709A1

    公开(公告)日:2012-06-14

    申请号:US13256787

    申请日:2010-03-16

    摘要: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.

    摘要翻译: 本发明涉及吡嗪并异喹啉衍生物的新化合物及其药学上可接受的盐。 更具体地,本发明涉及作为吡喹酮衍生物的新型吡嗪异喹啉衍生物。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。

    Deuterium-substituted xanthine derivatives and methods of use
    20.
    发明授权
    Deuterium-substituted xanthine derivatives and methods of use 有权
    氘取代黄嘌呤衍生物及其使用方法

    公开(公告)号:US08987442B2

    公开(公告)日:2015-03-24

    申请号:US13448930

    申请日:2012-04-17

    CPC分类号: A61K31/522 C07D473/06

    摘要: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

    摘要翻译: 本发明涉及作为取代黄嘌呤衍生物的新化合物及其药学上可接受的盐。 例如,本发明涉及作为己酮可可碱衍生物的新型取代黄嘌呤衍生物。 本发明还提供了包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗己酮可可碱和相关化合物有益的疾病和病症的方法中的用途。